Abstract 2144
Background
Some authors have suggested that the immunological response to postoperative infectious complications (ICs) enhances the viability of undetectable residual tumor cells after surgery, thereby inducing disease recurrence. We hypothesize that recurrence might not occur if neoadjuvant chemotherapy (NAC) treatment of micrometastases can prevent residual cancer cell growth. We evaluated whether or not NAC exerted prophylactic effects against the negative prognostic impact induced by postoperative ICs and assessed its interaction among subgroups of histological response.
Methods
We retrospectively examined 111 patients who received NAC followed by radical esophagectomy between January 2011 and September 2015. Risk factors for the recurrence-free survival (RFS) were examined by Cox proportional hazard analyses. Pathological responders to NAC were defined as those with a tumor disappearance of more than one-third of the initial tumor. Postoperative ICs were defined using the Clavien–Dindo classification.
Results
A pathological response to NAC was observed in 54 (48.6 %) patients. Forty-five patients (40.5%) developed postoperative ICs. The 3-year RFS were 68.8% in the patients who developed ICs and 38.6% in the patients who did not developed ICs (p = 0.001). The multivariate analysis demonstrated that postoperative ICs were a significant independent risk factor for the RFS (hazard ratio [HR], 2.368; 95% confidence interval [CI], 1.256-4.465, p = 0.008). In the subset analysis, in responders, the 3-year RFS were 63.2% in the patients who developed ICs and 71.5% in the patients who did not developed ICs (p = 0.524). In non-responders, the 3-year RFS were 29.3% in the patients who developed ICs and 65.4% in the patients who did not developed ICs (p = 0.006). The multivariate analysis demonstrated that postoperative ICs were a significant independent risk factor for RFS in the non-responders (HR, 2.632; 95% CI, 1.072-6.467, p = 0.035) but not in the responders (HR, 1.480; 95% CI, 0.469-4.667, p = 0.503).
Conclusions
These results suggested that response to NAC can eliminate the poor prognosis induced by postoperative ICs in esophageal cancer patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1571 - Thyroid Lobectomy versus Total Thyroidectomy among Early-Stage Papillary Thyroid Carcinoma Patient
Presenter: Sara Ahmed
Session: Poster Display session 2
Resources:
Abstract
5051 - Classification of thyroid nodule using DNA methylation profiling on tissue and circulating tumor DNA
Presenter: Shubin Hong
Session: Poster Display session 2
Resources:
Abstract
4155 - Durvalumab plus Tremelimumab for the Treatment of Patients (pts) with Refractory and Progressive Advanced Thyroid Carcinoma. A Phase II Multicohort Trial (DUTHY / GETNE T1812)
Presenter: Jorge Hernando Cubero
Session: Poster Display session 2
Resources:
Abstract